<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Quantitative real-time PCR (qPCR) is an accurate method to quantify Trypanosoma cruzi DNA and can be used to follow-up <z:e sem="disease" ids="C0242723" disease_type="Disease or Syndrome" abbrv="">parasitemia</z:e> in <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> (CD) patients undergoing chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>The Benznidazole Evaluation for Interrupting <z:e sem="disease" ids="C0041227" disease_type="Disease or Syndrome" abbrv="">Trypanosomiasis</z:e> (BENEFIT) study is an international, multicenter, randomized, double-blinded and placebo-controlled clinical trial to evaluate the efficacy of benznidazole (BZ) treatment in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> Chagas <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (<z:chebi fb="61" ids="32879">CCC</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>One important question to be addressed concerns the effectiveness of BZ in reducing overall parasite load in <z:chebi fb="61" ids="32879">CCC</z:chebi> patients, even in the absence of parasitological cure </plain></SENT>
<SENT sid="3" pm="."><plain>This report describes the evaluation of multiple procedures for DNA extraction and qPCR-based protocols aiming to establish a standardized methodology for the absolute quantification of T. cruzi DNA in <z:chebi fb="0" ids="42820">Guanidine</z:chebi>-EDTA blood (GEB) samples </plain></SENT>
<SENT sid="4" pm="."><plain>A panel of five primer sets directed to the T. cruzi nuclear satellite DNA repeats (Sat-DNA) and to the minicircle DNA conserved regions (kDNA) was compared in either SYBR Green or TaqMan systems </plain></SENT>
<SENT sid="5" pm="."><plain>Standard curve parameters such as, amplification efficiency, coefficient of determination and intercept were evaluated, as well as different procedures to generate standard samples containing pre-established T. cruzi DNA concentration </plain></SENT>
<SENT sid="6" pm="."><plain>Initially, each primer set was assayed in a SYBR Green qPCR to estimate parasite load in GEB samples from <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>The results achieved from Bayesian transmutability analysis elected the primer sets Cruzi1/Cruzi2 (p=0.0031) and Diaz7/Diaz8 (p=0.0023) coupled to the QIAamp DNA Kit extraction protocol (<z:chebi fb="48" ids="30563">silica</z:chebi> gel column), as the most suitable for monitoring <z:e sem="disease" ids="C0242723" disease_type="Disease or Syndrome" abbrv="">parasitemia</z:e> in these patients </plain></SENT>
<SENT sid="8" pm="."><plain>Comparison between the parasite burden of 150 GEB samples of BENEFIT patients from Argentina, Brazil and Colombia, prior to drug/placebo administration, was performed using Cruzi1/Cruzi2 primers in a SYBR Green approach </plain></SENT>
<SENT sid="9" pm="."><plain>The median <z:e sem="disease" ids="C0242723" disease_type="Disease or Syndrome" abbrv="">parasitemia</z:e> found in patients from Argentina and Colombia (1.93 and 2.31 parasite equivalents/mL, respectively) was around 20 times higher than the one estimated for the Brazilian patients (0.1 parasite equivalents/mL) </plain></SENT>
<SENT sid="10" pm="."><plain>This difference could be in part due to the complexity of T. cruzi genetic diversity, which is a factor possibly implicated in different clinical presentations of the disease and/or influencing <z:e sem="disease" ids="C0242723" disease_type="Disease or Syndrome" abbrv="">parasitemia</z:e> levels in infected individuals from different regions of Latin America </plain></SENT>
<SENT sid="11" pm="."><plain>The results of SYBR Green qPCR assays herein presented prove this methodology to be more cost efficient than the alternative use of internal fluorogenic probes </plain></SENT>
<SENT sid="12" pm="."><plain>In addition, its sensitivity and reproducibility are shown to be adequate to detect low <z:e sem="disease" ids="C0242723" disease_type="Disease or Syndrome" abbrv="">parasitemia</z:e> burden in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> </plain></SENT>
</text></document>